Outcome of High-Risk Myelodysplastic Syndrome After Azacitidine Treatment Failure

PURPOSE: Azacitidine (AZA) is the current standard of care for high-risk (ie, International Prognostic Scoring System high or intermediate 2) myelodysplastic syndrome (MDS), but most patients will experience primary or secondary treatment failure. The outcome of these patients has not yet been descr...

詳細記述

保存先:
書誌詳細
出版年:J Clin Oncol
主要な著者: Prébet, Thomas, Gore, Steven D., Esterni, Benjamin, Gardin, Claude, Itzykson, Raphael, Thepot, Sylvain, Dreyfus, François, Rauzy, Odile Beyne, Recher, Christian, Adès, Lionel, Quesnel, Bruno, Beach, C.L., Fenaux, Pierre, Vey, Norbert
フォーマット: Artigo
言語:Inglês
出版事項: American Society of Clinical Oncology 2011
主題:
ORIGINAL REPORTS
オンライン･アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC4859209/
https://ncbi.nlm.nih.gov/pubmed/21788559
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2011.35.8135
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!

類似資料